These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26379160)

  • 1. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study.
    Sheridan-Pereira M; Murphy J; Sloan J; Crispino G; Leahy A; Corcoran JD; Dempsey E; Elnazir B; Gavin P; Sharif F; Gul R; Satas S; Murphy J; Gormally S; Shanaa I; Waldron D; Mc Mahon P; Carson J; Blanken M; Bont L; Paes B
    Pediatr Infect Dis J; 2016 Jan; 35(1):19-24. PubMed ID: 26379160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H; Chung CH; Lin YJ; Lin CH
    PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
    Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
    Fryzek JP; Martone WJ; Groothuis JR
    Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
    Anderson EJ; Carbonell-Estrany X; Blanken M; Lanari M; Sheridan-Pereira M; Rodgers-Gray B; Fullarton J; Rouffiac E; Vo P; Notario G; Campbell F; Paes B
    Pediatr Infect Dis J; 2017 Feb; 36(2):160-167. PubMed ID: 27755464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
    Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
    Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
    Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D
    Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.
    Lee JH; Kim CS; Chang YS; Choi JH;
    J Korean Med Sci; 2015 Oct; 30 Suppl 1(Suppl 1):S104-10. PubMed ID: 26566351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.